NewsBenzingaUBS Maintains Buy on Chemed, Raises Price Target to $675 UBS Maintains Buy on Chemed, Raises Price Target to $675 Benzinga 2026.10.29 16:21 (GMT+0) Open on Benzinga Other news Citigroup Maintains Buy on Microsoft, Raises Price Target to $680 RBC Capital Maintains Outperform on Bausch & Lomb, Raises Price Target to $23 Citigroup Maintains Buy on Equinix, Raises Price Target to $1320 Marvell (MRVL) Stock Falls 15.01% Intraday, Now at $214.74 RBC Capital Maintains Outperform on Baker Hughes, Lowers Price Target to $70 Chipotle Posts Mixed Q3, Analysts View 2027 As 'A Prove-It Year'
